Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Midnight crypto slips below $0.04—How much of NIGHT’s rally remains?

Midnight crypto slips below $0.04—How much of NIGHT’s rally remains?

AMBCryptoAMBCrypto2026/10/23 21:33
By:AMBCrypto

Midnight’s NIGHT token traded near

$0.03894
on
October 23
, roughly
22%
below the
$0.05
level it reached earlier this month. Although at the time of this writing, it showed a small gain, the price remained below four cents.

The retreat has taken back part of a sharp rally from September’s much lower prices. NIGHT still holds substantial gains from before that surge, leaving buyers to wonder if it can establish a base before more of that advance unwinds. Let’s get into it.

Four cents has become harder to hold

NIGHT’s late-September climb carried it from around

$0.025
to above
$0.05
in early October. Between the end of September and early October, it saw an over
100%
rise, which took it to the
$0.05
price level. It was a huge rise, but trading since then has been less convincing.

@media only screen and (min-width: 0px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 50px; transition: min-height 0.3s ease; } } @media only screen and (min-width: 640px) and (min-height: 0px) { div[id^="bsa-zone_1774359638628-7_123456"] { min-height: 90px; } }
AD

The four-hour chart shows rebounds repeatedly fading as the month progressed. The latest attempt reached roughly

$0.04
3 before the price returned below
$0.04
, making it the first checkpoint.

Buyers were able to recover this level, but it was brief, and they have not been able to keep it there.

The chart showed that between

October 11 and the time of this writing
, its value has fallen by over
22%
from around
$0.05 to $0.039
.

The earlier rally has not disappeared

NIGHT remains well above the roughly

$0.020–$0.025
price area where it spent much of September, as seen on its daily chart.

For now, the closer test it faces is around the

$0.0377–$0.038
3 price level, which is around the latest session’s low and nearby trading lows. If it continues trading below that range, it would weaken the case that NIGHT is finding a floor.

In that scenario, the

$0.035–$0.036
price area could become the next area to watch. Also, earlier gains alone would offer little protection if buyers fail to respond.

What would change the picture?

A stronger recovery means that NIGHT has to regain the

$0.040–$0.041
price area and remain there when sellers return to try and take some gains.

That would move the price through the area where several short-term averages currently sit. More importantly, it would show buyers holding ground that they have recently surrendered.

The next test it would face would be around the

$0.043
price area, where the latest positive move stopped. Until it can move beyond that failed attempt, a positive daily candle only shows limited evidence of a turnaround.

The broader rally still has some gains left to defend, but the shorter-term chart shows that buyers have not ended October’s retreat.

Final Summary

NIGHT trades roughly 22% below $0.05, but it still retains most gains from September.

If it recovers the $0.040–$0.041 price area, the positive trend will be stronger.

 

 

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

"Predicting Your Prediction" Intensifies Tech Stock Sell-off! After $2.3 Trillion Market Value Evaporates, Has the "Hot Money" Mechanical Selling Still Not Subsided?

The Nasdaq 100 Index fell by 6.4%, wiping out $2.3 trillion in market capitalization. The core reason behind this decline is concerns that a comprehensive victory by the Democratic Party could lead to stricter regulations on AI development. Systematic funds, which typically follow the stock market's trend and respond to price fluctuations and momentum signals, were thus forced to reduce their investments, accelerating the downturn. The selling pressure from systematic strategies may not be over yet; it is expected that in the coming days, portfolios targeting volatility will sell at least $50 billion worth of stocks.

智通财经•2026/11/06 12:19

The midterm election tears open the "abyss" of AI trading, facing a moment of reckoning for trillion-dollar capital expenditure narratives

For months, investors have been worried about a series of risks behind the AI (artificial intelligence) capital expenditure "money tree." This week, the market finally pressed the panic selling button.

智通财经•2026/11/06 11:26
The midterm election tears open the "abyss" of AI trading, facing a moment of reckoning for trillion-dollar capital expenditure narratives